Literature DB >> 30808588

Calcilytics inhibit the proliferation and migration of human prostate cancer PC-3 cells.

Aya Yamamura1, Md Junayed Nayeem2, Motohiko Sato2.   

Abstract

The carcinogenesis and development of prostate cancer are mediated by enhanced Ca2+ signaling. In the present study, the pharmacological profile of the Ca2+-sensing receptor (CaSR) antagonists (calcilytics) was examined in human prostate cancer PC-3 cells. NPS2143 and Calhex 231 blocked extracellular Ca2+-induced increases in cytosolic [Ca2+]. NPS2143 and Calhex 231 inhibited cell proliferation (IC50 = 7.4 and 10.3 μM, respectively) and migration. The exposure to NPS2143 or Calhex 231 down-regulated CaSR protein expression. These results demonstrated that calcilytics inhibited cell proliferation/migration and down-regulated CaSR expression in human prostate cancer cells, suggesting their potential as novel therapeutic drugs for prostate cancer.
Copyright © 2019 The Authors. Production and hosting by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Calcilytic; Calcium-sensing receptor; Prostate cancer

Mesh：

Substances：

Year:  2019        PMID： 30808588     DOI： 10.1016/j.jphs.2019.01.008

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN： 1347-8613            Impact factor:   3.337


  6 in total

1.  A role for the calcium-sensing receptor in the expression of inflammatory mediators in LPS-treated human dental pulp cells.

Authors:  Shaofeng An; Yanhuo Chen; Ting Yang; Yihua Huang; Yiwei Liu
Journal:  Mol Cell Biochem       Date:  2022-06-14       Impact factor: 3.396

2.  Calcium-Sensing Receptor Antagonist NPS-2143 Inhibits Breast Cancer cell Proliferation, Migration and Invasion via Downregulation of p-ERK1/2, Bcl-2 and Integrin β1 and Induces Caspase 3/7 Activation.

Authors:  Mohammad A Y Alqudah; Marwah Azaizeh; Aref Zayed; Leen Asaad
Journal:  Adv Pharm Bull       Date:  2021-02-01

3.  The Calcium-Sensing Receptor is A Marker and Potential Driver of Neuroendocrine Differentiation in Prostate Cancer.

Authors:  Fanny Bery; Mathilde Cancel; Aurélie Chantôme; Roseline Guibon; Franck Bruyère; François Rozet; Karine Mahéo; Gaëlle Fromont
Journal:  Cancers (Basel)       Date:  2020-04-02       Impact factor: 6.639

4.  Calcium-Sensing Receptor Participates in High Glucose-Induced EndMT in Primary Human Aortic Endothelial Cells.

Authors:  Cheng Yuan; Lihua Ni; Xianqin Yang; Changjiang Zhang; Xiaoyan Wu
Journal:  Front Physiol       Date:  2021-01-15       Impact factor: 4.566

Review 5.  Metabolite Sensing GPCRs: Promising Therapeutic Targets for Cancer Treatment?

Authors:  Jesús Cosín-Roger; Dolores Ortiz-Masia; Maria Dolores Barrachina; Sara Calatayud
Journal:  Cells       Date:  2020-10-23       Impact factor: 6.600

6.  The bromodomain inhibitor JQ1+ reduces calcium-sensing receptor activity in pituitary cell lines.

Authors:  Kate E Lines; Anna K Gluck; Supat Thongjuea; Chas Bountra; Rajesh V Thakker; Caroline M Gorvin
Journal:  J Mol Endocrinol       Date:  2021-07-26       Impact factor: 5.098
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.